Because ATM and CHK2 inhibitors are largely ineffective in cancer clinical trials (58), development of activators of these kinases might afford more complete cell cycle control especially in conjunction with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors that have shown efficacy in the clinic (59). The gene discussed is ATM; the disease is cancer.